AMLX
Amylyx Pharmaceuticals, Inc. NASDAQ Listed Jan 7, 2022$15.20
Mkt Cap $1.3B
52w Low $4.20
76.4% of range
52w High $18.61
50d MA $15.40
200d MA $13.20
P/E (TTM)
-10.5x
EV/EBITDA
-6.4x
P/B
5.0x
Debt/Equity
0.0x
ROE
-47.4%
P/FCF
-9.3x
RSI (14)
—
ATR (14)
—
Beta
-0.21
50d MA
$15.40
200d MA
$13.20
Avg Volume
1.1M
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
43 Thorndike Street · Cambridge, MA 02141 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 16.06 | -0.5% | -5.4% | -3.1% | — | — | — | — |
| Mar 3, 2026 | AMC | -0.31 | -0.30 | +3.2% | 14.11 | -0.3% | +6.7% | -6.3% | -1.8% | +3.3% | +4.7% | — |
| Nov 6, 2025 | AMC | -0.43 | -0.37 | +14.0% | 12.46 | +0.8% | -1.2% | -1.1% | +4.1% | -2.8% | +0.7% | — |
| Aug 7, 2025 | AMC | -0.44 | -0.46 | -4.5% | 7.84 | -0.3% | -2.6% | +2.4% | +4.9% | +1.2% | +1.3% | — |
| May 8, 2025 | AMC | -0.45 | -0.42 | +6.7% | 4.58 | -1.5% | +0.7% | -0.2% | -2.4% | -3.1% | +3.9% | — |
| Mar 4, 2025 | AMC | -0.49 | -0.55 | -12.2% | 3.01 | +0.0% | +11.6% | +7.4% | +7.2% | -9.8% | +6.9% | — |
| Nov 7, 2024 | AMC | -0.47 | -0.53 | -12.8% | 6.54 | +4.0% | +2.4% | +4.9% | -11.2% | -9.0% | -11.6% | — |
| Aug 8, 2024 | AMC | -0.38 | -0.73 | -92.1% | 1.80 | +1.1% | +5.6% | +4.2% | +0.5% | +7.0% | +1.4% | — |
| May 9, 2024 | AMC | 0.24 | -0.46 | -291.7% | 1.89 | -0.5% | -6.9% | +3.4% | +2.7% | -2.7% | +0.5% | — |
| Feb 22, 2024 | AMC | 0.23 | 0.07 | -69.6% | 18.54 | +1.0% | -4.8% | -0.5% | +8.2% | +3.0% | -3.7% | — |
| Nov 9, 2023 | AMC | 0.44 | 0.30 | -31.8% | 12.26 | +2.4% | +1.8% | +3.7% | -3.2% | +4.5% | -7.3% | — |
| Aug 10, 2023 | AMC | 0.10 | 0.31 | +210.0% | 21.17 | -0.8% | +2.0% | -2.9% | +0.1% | -4.7% | +1.0% | — |
| May 11, 2023 | AMC | -0.24 | 0.02 | +108.3% | 28.82 | +5.8% | -4.0% | +1.7% | -3.4% | +2.2% | -3.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | Mizuho | Maintains | Outperform → Outperform | — | $16.88 | $17.05 | +1.0% | -3.4% | -4.4% | +2.6% | +0.1% | +2.8% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.66 | $13.94 | +2.0% | +1.2% | -2.6% | +0.6% | -5.8% | +8.9% |
| Mar 19 | Guggenheim | Maintains | Buy → Buy | — | $13.79 | $13.98 | +1.4% | +1.9% | -1.7% | -2.0% | +1.0% | +1.2% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.11 | $14.07 | -0.3% | +6.7% | -6.3% | -1.8% | +3.3% | +4.7% |
| Feb 20 | BofA Securities | Maintains | Buy → Buy | — | $14.02 | $14.45 | +3.1% | -0.1% | -0.8% | +5.8% | -2.3% | +6.2% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.22 | $14.86 | +4.5% | +4.7% | -3.6% | -2.0% | +0.4% | +0.1% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.46 | $12.56 | +0.8% | -1.2% | -1.1% | +4.1% | -2.8% | +0.7% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $15.17 | $15.17 | +0.0% | -1.5% | +2.8% | -0.5% | -3.1% | -3.4% |
| Oct 16 | Baird | Maintains | Outperform → Outperform | — | $15.79 | $15.93 | +0.9% | -3.9% | -1.5% | +2.8% | -0.5% | -3.1% |
| Oct 3 | BofA Securities | Maintains | Buy → Buy | — | $13.29 | $13.56 | +2.0% | +1.0% | -5.4% | +6.3% | -0.1% | +7.3% |
| Sep 16 | Goldman Sachs | Maintains | Buy → Buy | — | $11.85 | $11.98 | +1.1% | +0.9% | +6.8% | +3.8% | +0.5% | +0.0% |
| Sep 15 | Guggenheim | Maintains | Buy → Buy | — | $11.65 | $12.05 | +3.4% | +1.7% | +0.9% | +6.8% | +3.8% | +0.5% |
| Aug 28 | BofA Securities | Maintains | Buy → Buy | — | $9.45 | $9.41 | -0.4% | -0.3% | -0.4% | +6.4% | -1.4% | +1.1% |
| May 14 | Mizuho | Maintains | Outperform → Outperform | — | $4.49 | $4.60 | +2.4% | -3.1% | +3.9% | +7.1% | +10.7% | +3.0% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.58 | $4.51 | -1.5% | +0.7% | -0.2% | -2.4% | -3.1% | +3.9% |
| May 7 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $4.65 | $5.10 | +9.7% | +4.7% | -6.0% | +0.7% | -0.2% | -2.4% |
| Apr 7 | Mizuho | Upgrade | Neutral → Outperform | — | $3.43 | $3.46 | +0.9% | +0.9% | -4.3% | +5.4% | +0.0% | +4.6% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.01 | $3.01 | +0.0% | +11.6% | +7.4% | +7.2% | -9.8% | +6.9% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.26 | $5.26 | +0.0% | -5.5% | +3.4% | -5.1% | -7.6% | -3.1% |
| Nov 18 | Baird | Upgrade | Neutral → Outperform | — | $4.76 | $5.23 | +9.9% | +11.3% | -1.5% | +0.2% | -0.8% | +1.5% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.54 | $6.80 | +4.0% | +2.4% | +4.9% | -11.2% | -9.0% | -11.6% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.92 | $4.07 | +3.8% | +21.9% | -2.5% | -2.8% | +9.5% | -1.2% |
| Jul 12 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.28 | $2.32 | +1.8% | -5.3% | +0.0% | +9.3% | -10.2% | -5.7% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.65 | $1.69 | +2.4% | +25.5% | +10.1% | -5.3% | +0.0% | +9.3% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.78 | $1.80 | +1.1% | +2.8% | +1.1% | -1.1% | +5.5% | -1.6% |
| May 14 | Mizuho | Maintains | Neutral → Neutral | — | $1.82 | $1.83 | +0.5% | +2.7% | -2.7% | +0.5% | +0.0% | +0.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.89 | $1.88 | -0.5% | -6.9% | +3.4% | +2.7% | -2.7% | +0.5% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.46 | $2.45 | -0.4% | -6.9% | -8.3% | -1.4% | -2.9% | -0.5% |
| Apr 11 | Baird | Maintains | Neutral → Neutral | — | $2.46 | $2.45 | -0.4% | -6.9% | -8.3% | -1.4% | -2.9% | -0.5% |
| Apr 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.62 | $2.65 | +1.1% | +2.7% | -0.7% | -7.9% | -6.9% | -8.3% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.80 | $3.67 | -3.4% | -9.5% | +0.0% | -7.8% | +2.2% | -11.7% |
| Mar 11 | Goldman Sachs | Downgrade | Buy → Neutral | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 11 | Baird | Downgrade | Outperform → Neutral | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 11 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 11 | Deutsche Bank | Maintains | Buy → Buy | — | $3.36 | $3.33 | -0.9% | +13.1% | -9.5% | +0.0% | -7.8% | +2.2% |
| Mar 8 | Evercore ISI | Downgrade | Outperform → In Line | — | $18.97 | $2.99 | -84.2% | -82.3% | +13.1% | -9.5% | +0.0% | -7.8% |
| Mar 8 | Mizuho | Maintains | Buy → Buy | — | $18.97 | $2.99 | -84.2% | -82.3% | +13.1% | -9.5% | +0.0% | -7.8% |
| Dec 21 | Mizuho | Maintains | Buy → Buy | — | $13.81 | $14.02 | +1.5% | +1.0% | +3.9% | -1.8% | +2.1% | +1.4% |
| Nov 10 | Goldman Sachs | Maintains | Buy → Buy | — | $12.26 | $12.56 | +2.4% | +1.8% | +3.7% | -3.2% | +4.5% | -7.3% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.26 | $12.56 | +2.4% | +1.8% | +3.7% | -3.2% | +4.5% | -7.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.17 | $21.01 | -0.8% | +2.0% | -2.9% | +0.1% | -4.7% | +1.0% |
| Jul 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.83 | $22.88 | +0.2% | -2.5% | +1.3% | +4.0% | -0.3% | -2.5% |
| Jul 24 | Goldman Sachs | Upgrade | Neutral → Buy | — | $22.55 | $24.16 | +7.1% | +1.6% | -1.8% | +1.5% | -2.5% | +1.3% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.04 | $24.27 | +1.0% | +2.7% | -1.0% | +3.0% | +0.4% | +1.1% |
| May 15 | Mizuho | Maintains | Buy → Buy | — | $27.67 | $28.13 | +1.7% | +1.7% | -3.4% | +2.2% | -3.4% | -0.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.82 | $30.50 | +5.8% | -4.0% | +1.7% | -3.4% | +2.2% | -3.4% |
| Mar 31 | Mizuho | Maintains | Buy → Buy | — | $27.71 | $28.50 | +2.9% | +5.9% | -2.5% | +0.1% | -2.9% | +4.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.17 | $37.19 | +19.3% | +9.4% | -1.5% | -4.5% | -5.6% | +4.9% |
| Mar 14 | Citigroup | Maintains | Buy → Buy | — | $31.17 | $37.19 | +19.3% | +9.4% | -1.5% | -4.5% | -5.6% | +4.9% |
| Mar 14 | Goldman Sachs | Maintains | Neutral → Neutral | — | $31.17 | $37.19 | +19.3% | +9.4% | -1.5% | -4.5% | -5.6% | +4.9% |
No insider trades available.
8-K · 2.02
!! High
Amylyx Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Amylyx Pharmaceuticals disclosed quarterly earnings results via 8-K filing, with detailed financial performance metrics available in the attached press release exhibit for investor review.
May 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Amylyx Pharmaceuticals disclosed its strategic focus on endocrine and neurodegenerative disease therapies, signaling management's commitment to high-risk, high-reward drug development that could drive significant long-term value if successful.
Mar 24
8-K
Amylyx Pharmaceuticals, Inc. -- 8-K Filing
Amylyx Pharmaceuticals advanced its avexitide program for post-bariatric hypoglycemia and progressed its pipeline during 2025, demonstrating operational momentum for the clinical-stage biotech company.
Mar 3
Data updated apr 24, 2026 5:49pm
· Source: massive.com